Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Taking a closer look at astrocytes and autism
These glial cells are increasingly linked to neurodevelopmental conditions and the regulation of social behaviors and anxiety.
Taking a closer look at astrocytes and autism
These glial cells are increasingly linked to neurodevelopmental conditions and the regulation of social behaviors and anxiety.
Neuro’s ark: Sounding out the evolution of hearing with geckos
Catherine Carr explains her discovery that geckos retain a vibration-sensing pathway previously thought to be lost when animals moved onto land.
Neuro’s ark: Sounding out the evolution of hearing with geckos
Catherine Carr explains her discovery that geckos retain a vibration-sensing pathway previously thought to be lost when animals moved onto land.
Researchers retract multisensory learning paper after failed replications
Even though one set of experiments did not hold up, the authors stand by the original conclusions of the work and plan to resubmit it as a new paper.
Researchers retract multisensory learning paper after failed replications
Even though one set of experiments did not hold up, the authors stand by the original conclusions of the work and plan to resubmit it as a new paper.